The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Open accessAbstract
BACKGROUND: Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. METHODS: ASPECT-cIAI (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) was a prospective, randomized, double-blind trial. Hospitalized patients with cIAI received either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours or meropenem (1 g) every 8 hours intravenously for 4-14 days. The prospectively defined objectives were to demonstrate statistical noninferiority in clinical cure rates at the test-of-cure visit (24-32 days from start of therapy) in the microbiological intent-to-treat (primary) and microbiologically evaluable (secondary) populations using a noninferiority margin of 10%. Microbiological outcomes and safety were also evaluated. RESULTS: Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/389] vs 87.3% [364/417]; weighted difference, -4.2%; 95% confidence interval [CI], -8.91 to .54) and secondary (94.2% [259/275] vs 94.7% [304/321]; weighted difference, -1.0%; 95% CI, -4.52 to 2.59) endpoints, meeting the prespecified noninferiority margin. In patients with ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, respectively, and 100% (13/13) and 72.7% (8/11) in patients with CTX-M-14/15 ESBLs. The frequency of adverse events (AEs) was similar in both treatment groups (44.0% vs 42.7%); the most common AEs in either group were nausea and diarrhea. CONCLUSIONS: Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI, including infections caused by multidrug-resistant pathogens. CLINICAL TRIALS REGISTRATION: NCT01445665 and NCT01445678.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,827
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Self-citationKumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., et al. (2009) · Chest · doi:10.1378/chest.09-0087 · Cited by 1,187
Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., Gilbert, D., & for the Infectious Diseases Society of America (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit152 · Cited by 700
Woerther, P.-L., Burdet, C., Chachaty, E., & Andremont, A. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-13 · Cited by 686
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Surgical Infections · doi:10.1089/sur.2009.9930 · Cited by 623
Self-citation
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
How to manage Pseudomonas aeruginosa infections
Bassetti, M., Vena, A., Croxatto, A., Righi, E., & Guery, B. (2018) · Drugs in Context · doi:10.7573/dic.212527 · Cited by 746
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Doi, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz830 · Cited by 652
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
van Duin, D., & Bonomo, R. A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw243 · Cited by 549
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
New β-Lactam–β-Lactamase Inhibitor Combinations
Yahav, D., Giske, C. G., Grāmatniece, A., Abodakpi, H., Tam, V. H., & Leibovici, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-20 · Cited by 521
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1478 · Cited by 441
Mazuski, J. E., Gasink, L. B., Armstrong, J., Broadhurst, H., Stone, G. G., Rank, D., Llorens, L., Newell, P., & Pachl, J. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw133 · Cited by 393
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab295 · Cited by 390
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Kaye, K. S., & Pogue, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1636 · Cited by 383
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Treatment of Infections Due to MDR Gram-Negative Bacteria
Bassetti, M., Peghin, M., Vena, A., & Giacobbe, D. R. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00074 · Cited by 326
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections
Ma, Y., Wang, C., Li, Y., Li, J., Wan, Q., Chen, J., Tay, F. R., & Niu, L. (2020) · Advanced Science · doi:10.1002/advs.201901872 · Cited by 314
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0220 · Cited by 313
Antibiotic strategies in the era of multidrug resistance
Karam, G., Chastre, J., Wilcox, M. H., & Vincent, J.-L. (2016) · Critical Care · doi:10.1186/s13054-016-1320-7 · Cited by 296
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00151 · Cited by 288
Haidar, G., Philips, N. J., Shields, R. K., Snyder, D., Cheng, S., Potoski, B. A., Doi, Y., Hao, B., Press, E. G., Cooper, V. S., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix182 · Cited by 277
Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2016.4237 · Cited by 276
Self-citationTherapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Kunz Coyne, A. J., El Ghali, A., Holger, D., Rebold, N., & Rybak, M. J. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00591-2 · Cited by 275
Wright, H., Bonomo, R. A., & Paterson, D. L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.09.001 · Cited by 256
For the DURAPOP Trial Group, Montravers, P., Tubach, F., Lescot, T., Veber, B., Esposito-Farèse, M., Seguin, P., Paugam, C., Lepape, A., Meistelman, C., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5088-x · Cited by 173
Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Critical Care Medicine · doi:10.1097/ccm.0000000000007075 · Cited by 117
Metadata
- Authors
- Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., & Eckmann, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-02-10
- Volume
- 60
- Issue
- 10
- Pages
- 1462-1471
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1969500929
- Cited by
- 420
- References
- 36
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.